TransMedics Group (TMDX) Expected to Announce Earnings on Tuesday

TransMedics Group (NASDAQ:TMDX) will likely be posting its Q4 2025 results after the market closes on Tuesday, February 24th. Analysts expect TransMedics Group to post earnings of $0.41 per share and revenue of $155.2790 million for the quarter. Parties may visit the the company’s upcoming Q4 2025 earning results page for the latest details on the call scheduled for Tuesday, February 24, 2026 at 4:30 PM ET.

TransMedics Group Stock Performance

NASDAQ TMDX opened at $134.25 on Friday. TransMedics Group has a 1 year low of $62.07 and a 1 year high of $156.00. The firm has a market capitalization of $4.59 billion, a price-to-earnings ratio of 54.35 and a beta of 2.06. The company has a current ratio of 7.69, a quick ratio of 7.13 and a debt-to-equity ratio of 1.43. The firm’s 50 day simple moving average is $132.50 and its 200 day simple moving average is $125.87.

Insiders Place Their Bets

In other TransMedics Group news, Director David Weill sold 5,000 shares of the stock in a transaction dated Wednesday, December 3rd. The stock was sold at an average price of $138.64, for a total value of $693,200.00. Following the completion of the transaction, the director directly owned 12,134 shares in the company, valued at approximately $1,682,257.76. This trade represents a 29.18% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CFO Gerardo Hernandez sold 920 shares of TransMedics Group stock in a transaction dated Thursday, December 4th. The shares were sold at an average price of $139.62, for a total value of $128,450.40. Following the sale, the chief financial officer directly owned 15,064 shares in the company, valued at $2,103,235.68. The trade was a 5.76% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 8,920 shares of company stock valued at $1,257,310 in the last 90 days. Corporate insiders own 7.00% of the company’s stock.

Institutional Investors Weigh In On TransMedics Group

A number of institutional investors have recently added to or reduced their stakes in TMDX. Harvest Fund Management Co. Ltd acquired a new position in TransMedics Group in the 3rd quarter valued at approximately $29,000. Allworth Financial LP grew its stake in shares of TransMedics Group by 74.3% in the third quarter. Allworth Financial LP now owns 265 shares of the company’s stock worth $30,000 after purchasing an additional 113 shares during the last quarter. Parallel Advisors LLC grew its stake in shares of TransMedics Group by 42.1% in the fourth quarter. Parallel Advisors LLC now owns 280 shares of the company’s stock worth $34,000 after purchasing an additional 83 shares during the last quarter. US Bancorp DE increased its holdings in TransMedics Group by 24.2% in the third quarter. US Bancorp DE now owns 533 shares of the company’s stock valued at $60,000 after purchasing an additional 104 shares during the period. Finally, Atlas Capital Advisors Inc. bought a new position in TransMedics Group during the 4th quarter worth $61,000. 99.67% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

A number of equities research analysts have weighed in on the company. Piper Sandler reaffirmed an “overweight” rating on shares of TransMedics Group in a report on Monday, December 22nd. Canaccord Genuity Group upped their price objective on TransMedics Group from $147.00 to $148.00 and gave the stock a “buy” rating in a research report on Wednesday, December 17th. Needham & Company LLC raised their price objective on TransMedics Group from $148.00 to $166.00 and gave the company a “buy” rating in a research note on Monday, December 8th. Wall Street Zen upgraded TransMedics Group from a “hold” rating to a “buy” rating in a research report on Saturday, February 14th. Finally, Morgan Stanley increased their target price on shares of TransMedics Group from $123.00 to $135.00 and gave the stock an “equal weight” rating in a report on Tuesday, December 2nd. Six investment analysts have rated the stock with a Buy rating and four have given a Hold rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $144.25.

TransMedics Group Company Profile

TransMedics Group, Inc is a medical device company headquartered in Andover, Massachusetts, that specializes in advanced organ preservation and transport systems for transplantation. The company’s flagship technology, the Organ Care System (OCS), maintains donor organs in a near-physiologic, warm, beating state during transportation, with the aim of extending preservation times and improving post‐transplant outcomes. TransMedics’ solutions address a critical need in transplantation by reducing ischemic injury and expanding the donor organ pool.

TransMedics currently markets two commercially available OCS platforms.